Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:36 PM
Ignite Modification Date: 2025-12-24 @ 10:36 PM
NCT ID: NCT03935035
Eligibility Criteria: Inclusion Criteria: * Participant is aged 12-17 years old * Main presenting problem is PTSD and there is a not a co-morbid problem that would preclude treatment of PTSD. * PTSD symptoms related to a single trauma * Participant has access to compatible smartphone and larger computing device (e.g. laptop, desktop computer, iPad) with internet access. * Participant is proficient in speaking and writing in the English language, sufficient to participate in treatment without an interpreter. Exclusion Criteria: * Brain damage assessed by clinical interview with parents / carers * Intellectual disability assessed by clinical interview with parents / carers * Pervasive developmental disorder or neurodevelopmental disorder assessed by clinical interview with parents / carers * Other psychiatric diagnosis that requires treatment before PTSD, determined by clinical interview and questionnaires * Moderate to high risk to self assessed in clinical interview * Ongoing trauma-related threat assessed in clinical interview * Started treatment with psychotropic medication, or changed medication, within the last 2 months, assessed in clinical interview * Currently receiving another psychological treatment, assessed in interview * Have already received Trauma Focused CBT in relation to the same traumatic event that the young person is currently seeking treatment for.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 12 Years
Maximum Age: 17 Years
Study: NCT03935035
Study Brief:
Protocol Section: NCT03935035